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Abstract: Targeting epidermal growth factor receptor (EGFR) with tyrosine kinase inhibitors (TKI)
has been widely exploited to disrupt aberrant phosphorylation flux in cancer. However, a bottleneck
of potent TKIs is the acquisition of drug resistance mutations, secondary effects, and low ability
to attenuate tumor progression. We have developed an alternative means of targeting EGFR
that relies on protein degradation through two consecutive routes, ultimately leading to cancer
cell detachment-related death. We describe furfuryl derivatives of 4-allyl-5-[2-(4-alkoxyphenyl)-
quinolin-4-yl]-4H-1,2,4-triazole-3-thiol that bind to and weakly inhibit EGFR tyrosine phosphorylation
and induce strong endocytic degradation of the receptor in cancer cells. The compound-promoted
depletion of EGFR resulted in the sequestration of non-phosphorylated Bim, which no longer ensured
the integrity of the cytoskeleton machinery, as shown by the detachment of cancer cells from the
extracellular matrix (ECM). Of particular note, the longer CH3(CH2)n chains in the terminal moiety of
the anti-EGFR molecules confer higher hydrophobicity in the allosteric site located in the immediate
vicinity of the catalytic pocket. Small compounds accelerated and enhanced EGFR and associated
proteins degradation during EGF and/or glutamine starvation of cultures, thereby demonstrating
high potency in killing cancer cells by simultaneously modulating signaling and metabolic pathways.
We propose a plausible mechanism of anti-cancer action by small degraders through the allosteric site of
EGFR. Our data represent a rational and promising perspective in the treatment of aggressive tumors.
Keywords: cancer; targeting chemotherapy; receptor tyrosine kinase; allosteric site; protein degraders;
autophagy; cytoskeleton; anoikis; EGFR; Bim
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1. Introduction
Epidermal growth factor receptor, EGFR, belongs to a family of ErbB transmembrane proteins that
govern signaling pathways and the expression of genes involved in the proliferation, survival, adhesion,
and motility of cells [1]. A cognate ligand EGF binding to the extracellular region of EGFR results in
receptor dimerization, leading to the activation of the ATP-binding site and autophosphorylation of
tyrosine residues in the cytoplasmic region of the receptor. Mutations resulting in EGFR overexpression
have been shown to be associated with the progression of different types of cancer; therefore, targeting
this protein has been an important issue in medicinal chemistry in recent decades [2].
Potent ATP-competitive TKIs, including FDA-approved gefitinib, have been developed to inhibit
the EGFR catalytic site [3]. TKIs with a covalent mode of action, such as canertinib, have also been
designed to bind to a nucleophilic cysteine (Cys797) in proximity to the EGFR catalytic site [4].
Reversible and irreversible covalent inhibitors efficiently block the EGFR catalytic site and prolong the
attenuation of downstream signaling cascades compared with competitive inhibitors [5]. However,
a bottleneck of all potent EGFR TKIs is the acquisition of drug resistance mutations in the catalytic
pocket or other sites of the receptor [6], as well as secondary effects, and low ability to attenuate tumor
progression, as shown by numerous laboratory and clinical studies.
A clue to understanding the inhibition of the tyrosine kinase activity of EGFR by TKIs is the
finding that the activation of the ATP-binding site is related to the action of hydrogen peroxide (H2O2)
that is generated during cognate ligand binding to the receptor [7,8]. Indeed, the binding of EGF to
EGFR promotes the transformation of O2 to H2O2 through the membrane-located NADPH oxidase
Nox2; then, this reactive oxygen species reacts with Cys797, leading to the transition of the thiolate
anion (Cys-S) to sulfenic acid (Cys-SOH), which is required for the activation of the ATP-binding
site [8]. Recent data have shown that the amino acid Arg841 in the catalytic loop determines the
dynamic structural alterations preceding the appropriate positioning of Cys797 to be sulfenylated [9].
Notably, H2O2 has also been shown to inhibit the catalytic site in protein tyrosine phosphatase PTP-1B;
this inhibition contributes to enhancing the phosphorylation of the PTP-1B substrate EGFR [10].
Ligand-independent phosphorylation of EGFR has also been described in cells treated with small
chemicals [11–13]. In particular, EGFR activation with 4-nitro-benzoxadiazole derivatives has been
shown to rely on the generation of H2O2 by cytoplasmic superoxide dismutase in cancer cells [14].
Overall, these findings have suggested that the reactive hydrogen peroxide that is generated through a
variety of metabolic reactions could unpredictably enhance the phosphorylation flux in EGFR-triggered
pathways and could extinguish the effects of TKIs on cancer cells, thereby diminishing therapeutic
efficacy. Therefore, anti-EGFR compounds that reduce receptor protein levels might be an alternative
strategy to interrupt aberrant signaling in cancer cells.
EGFR endocytosis is an autophagic process, classified as microautophagy, which governs the fate
of the receptor in cells [15]. Ligand-bound EGFR undergoes endocytosis followed by recycling and/or
degradation of the receptor by proteolytic enzymes in lysosomes fused to endosomes [16]. Low doses
of EGF activate clathrin-dependent endocytosis, whereas high doses of the cognate ligand promote both
clathrin-dependent and clathrin-independent endocytosis [17]. Gefitinib has been shown to induce
autophagy by suppression of EGF-stimulated endocytosis [18] and to induce atypical necroptosis in
amino acid starved lung cancer cells [19].
EGFR phosphorylation status determines the functional state of integrins, which are
transmembrane receptors that mediate cell adhesion to the ECM [20]. EGF binding to EGFR mediates
the MAPK/ERK pathway leading to phosphorylation of the Bcl-2 interacting mediator (Bim), the sensor
protein, which subsequently binds to microtubules and actin to provide the attachment of α/β-integrins
to the ECM and the integrity of cytoskeleton [21]. Bim-mediated phosphorylation of the cytoskeleton
is an integral part of anoikis, a programmed apoptotic death caused by cell detachment from the
ECM [22]. The phosphorylation of EGFR-regulated signaling is dynamically affected by a variety of
environmental factors, such as the availability of cognate ligands of the receptor or amino acids in
a growth medium [23]. Other signaling and metabolic pathways also affect Bim phosphorylation at
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different sites of the protein isomers [24,25]. Compared with healthy cells, cancer cells possess a higher
tolerance to anoikis, which is important for the metastatic progression of inflammatory tumors [26].
Therefore, there is a possible pharmacological window to disrupt aberrant signaling in
tumors by targeting EGFR degradation with small chemical molecules. Recently, we synthesized
polyfunctionalized heterocyclic compounds by combining three molecular scaffolds into one molecule
that can bind EGFR [27]. Herein, we demonstrate that some compounds behave as weak inhibitors
of EGFR phosphorylation and show enhanced degradation of the receptor and cytoskeletal proteins,
leading to cancer cell detachment-related death. We provide a plausible explanation of the action of
the compounds to highlight the rationale behind targeting EGFR degradation in anticancer therapy.
2. Results
2.1. Synthesis of Polyfunctionalized Heterocyclic Compounds
Furfuryl derivatives of 4-allyl-5-[2-(4′-alkoxyphenyl)quinolin-4-yl]-4H-1,2,4-triazol-3-thiol were
synthesized by combining quinoline, furan and triazole scaffolds in a single molecule, suggesting
that the action of the novel compounds will differ from known anti-EGFR TKIs [27]. To intensify this
difference, we connected alkyl ether substituents of different lengths to the benzene ring at the extremity
of new structures, which might enhance local hydrophobicity of the bound EGFR and sensitize the
receptor protein to the action of proteases. The synthetic route of compounds is shown in Figure 1.
Figure 1. Synthetic route and structures of furfuryl derivatives of 4-allyl-5-[2-(4-alkoxyphenyl)-
quinolin-4-yl]-4H-1,2,4-triazole-3-thiol. The AlogP values were calculated with Discovery Studio
4.0 software.
The starting materials for synthesis were hydrazides of 2-(4-alkoxyphenyl)quinolin-4-carboxylic
acids (1–5) [28], which were delivered in conjunction with allyl isothiocyanate in ethanol, resulting
in the synthesis of N4-allylthiosemicarbazide 2-(4-alkoxyphenyl)quinolin-4-carboxylic acids (6–10).
These compounds were further cyclized with KOH into 4-allyl-3-[2-(4-alkoxyphenyl)quinoline-4-yl]-
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4,5-dihydro-1H-1,2,4-triazole-5-thiones (11–15) [29]. The reaction of compounds 11–15 with the methyl
ester of 5-chloromethylfuran-2-carboxylic acid in the presence of equimolar amounts of KOH yielded
only S-substituted derivatives (VM17-VM21). In the latter structures, the ester group was hydrolyzed
with potassium hydroxide in water-methanol medium to a carboxyl group (VM22-VM26).
2.2. Identification of Compounds That Decrease EGFR Levels in Cancer Cells
To assess the ability of new compounds to modulate EGFR expression and phosphorylation,
we used the triple-negative breast cancer cell line MDA-MB-468, in which the receptor protein is
overexpressed compared with the low expression of its counterpart ErbB2 [30]. The cells were
grown in DMEM deprived of fetal bovine serum (FBS) overnight and treated with 100 µM of the
compounds followed by EGFR stimulation with its cognate ligand EGF. Western blotting revealed that
two compounds, VM25 and VM26, significantly suppressed tyrosine phosphorylation and decreased
receptor expression levels (Figure 2a). No effects were detected with compounds VM20 and VM21,
which contain the ester group instead of the carboxylic acid in VM25 and VM26, respectively (Figure 1).
In cells incubated with compound VM25 or VM26 without further stimulation with EGF, EGFR
levels decreased compared with the cells incubated with vehicle (0.1% dimethylsulfoxyde, DMSO)
(Figure 2b). A covalent inhibitor of EGFR, canertinib, which was used as a control, suppressed tyrosine
phosphorylation of EGFR without reducing EGFR levels under the conditions used.
Figure 2. Small compounds decrease epidermal growth factor receptor (EGFR) expression in
MDA-MB-468 cells. (a) Serum-starved MDA-MB-468 cells were incubated with vehicle (veh) and
selected compounds at a concentration of 100 µM for 2 h and then stimulated with 200 ng/mL EGF
for 10 min. (b) Comparison of the action of the compounds VM25 and VM26 with canertinib (1 µM).
(c) Compounds VM25 and VM26 exhibit dose-dependent effects on EGFR expression.
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A comparative evaluation of the two active compounds showed that the phosphorylation levels at
Tyr1068 and EGFR expression decreased in a dose-dependent manner in serum-starved MDA-MB-468
cells treated with the compounds and then stimulated with EGF (Figure 2c). The cells also gradually
suppressed the tyrosine phosphorylation of other protein kinases, as detected with the anti-pTyr
antibody, and compound VM26 was more active than VM25. Compound VM26 was also active in
non-small-cell lung-cancer (NSCLC) A549 cells (Supplementary Figure S1). Notably, the decrease in
EGFR levels was accompanied by a decrease in the levels of other proteins, such as Hsp90α, HDAC2,
andβ-actin, in cells treated with higher concentrations of the compounds (Figure 2c and Supplementary
Figure S1).
The ability of the active compounds VM25 and VM26 to simultaneously suppress tyrosine
phosphorylation and to reduce EGFR levels and other functionally unrelated proteins suggested that
the small molecules induce protein degradation by first targeting EGFR in cancer cells.
2.3. Small Compounds Activate Endocytosis of EGFR
MDA-MB-468 cells were transfected with EGFR-specific siRNA and used to assess the protein
levels after exposure to the small compounds. Despite the moderate efficacy of siRNA silencing
(apparently related to the high copy number of EGFR in the MDA-MB-468 cell line), the cells displayed a
remarkable decrease in EGFR and Hsp90α levels and less in β-actin levels when exposed to compound
VM26 (this decrease was less apparent with compound VM25) in serum-deprived culture compared
with the vehicle (Figure 3a). In this assay, we also assessed the ubiquitin-like proteins LC3α/β by taking
into consideration that LC3β accumulation correlates with increasing numbers of autophagosomes and
therefore, it can be used for monitoring autophagy [31]. A relatively intense 16-kDa band corresponding
to LC3β was detected in the cells, indicating the activation of EGFR endocytosis. The shift of LC3α to
LC3β was more pronounced with scrambled siRNA than with EGFR-specific siRNA in cells treated
with small compounds, suggesting that knockdown of the receptor reduced the autophagy response.
The quantification of the ratio of LC3β to β-actin showed that the relative levels of the autophagy
biomarker were higher by approximately 50% after exposure to the compounds VM25 or VM26 in cells
transfected with scrambled siRNA compared with the vehicle (Figure 3b). Hence, compounds VM25
or VM26 could induce the degradation of EGFR and associated nutrient-prone proteins in cancer cells
during growth in the serum-deprived medium.
To verify that the activation of LC3βwas a result of the action of small compounds, the FBS-starved
cells were incubated with a lower concentration of VM26 for a shorter time, and the autophagy biomarker
was analyzed with immunofluorescence microscopy. The LC3β protein emitted a strong fluorescent
signal upon exposure to VM26 relative to the vehicle (Figure 3c), indicating that the penetration of a
small compound resulted in a rapid response of the autophagy mechanism in cells. Indeed, the spots,
clearly visible near the plasma membrane on the enlarged image (Supplementary Figure S2), represent
likely autophagosomes that could be formed by invagination of small compound/EGFR-bound
complexes at the early stages of microautophagy of the transmembrane receptor.
Next, immunofluorescence imaging confirmed that small compounds specifically target EGFR in
starved cancer cells. In control experiments with the vehicle, the receptor was found exclusively in the
cytoplasmic membrane of nonpermeabilized cells or predominantly in the cytoplasmic membrane of
permeabilized cells (Figure 4a,b and Supplementary Figure S3a,b). In contrast, after a short exposure
to low concentrations of VM23 or VM26, the fluorescence signal emitted by EGFR decreased in the
cytoplasmic membrane and increased in the cytoplasm (Figure 4c,d and Supplementary Figure S3c,d).
Moreover, the second fluorescent area illuminated around nuclei was identified as two new peaks
on signal profiling curves (to the right in the images). The dispersion of fluorescence signals in the
cytoplasm, as well as alternating low peaks on profiling curves, indicated that a portion of EGFR is
released in this compartment. Notably, these features were associated with the reduction of the size
of cells and nuclei upon exposure to the compounds. The measurement of the two-dimensional axis
of nuclei showed a statistically significant decrease in their size and surface square after exposure
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to VM26 compared with the vehicle (Figure 4e and Supplementary Table S1). This morphological
change strongly suggested that exposure to small compounds rapidly results in the diminution of the
cell contacting surface with the plate surface, which in the biological sense indicates the loss of the
adhesion capacity of cells to the ECM.
Figure 3. Small compounds activate microautophagy in cancer cells. (a) Western blot of proteins
extracted from MDA-MB-468 cells after transfection with EGFR siRNAs or scrambled siRNAs and
exposure to 25 µM VM25 and VM26 for 2 h in serum-deprived Dulbecco’s Modified Eagle Medium
(DMEM). (b) Relative levels of proteins were estimated as the ratio to β-actin and adjusted to the
vehicle-treated cells normalized to 100%. (c) Immunofluorescence detection of LC3α/β in MDA-MB-468
cells exposed to 2.5 µM VM26 for 1 h. The size bar is equal to 10 µm.
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Figure 4. EGFR rapidly responds to the chemical invasion of small compounds in cancer cells.
Immunofluorescence detection was carried out with anti-EGFR mAb (the epitope in the extracellular
domain). Fluorescence in nonpermeabilized (a) and permeabilized (b) cells after exposure to vehicle
and in permeabilized cells after exposure to VM23 (c) and VM26 (d). MDA-MB-468 cells were incubated
with VM23 and VM26 as described in Figure 3c. Profiling curves of fluorescent signal distribution in
representative cells are shown with dashes in merge. (e) Boxplot histogram of a 2D square of nuclei
surfaces upon exposure to vehicle and VM26. Sav is the average square of the nuclear surface in cells.
The size bar is equal to 10 µm.
2.4. Small Compounds Promote Cancer Cell Detachment
We noticed that incubation of cancer cells with high concentrations of compounds in FBS-deprived
medium for approximately two hours lowered the levels of β-actin, which was used as a loading
control in Western blot experiments (Figure 2). Given that β-actin is a key cytoskeletal protein, we
assumed that the analysis of cell extracts with the same total protein concentration to be loaded does
not reflect the actual protein levels in a typically adherent cell line, such as MDA-MB-468, if cells
detach from the plate surface, mimicking ECM. Therefore, we decided to load the same volumes of
cell extracts, regardless of the total protein concentration, in order to better elucidate the subsequent
processes caused by the depletion of EGFR in the attached cells and detached cells after treatment with
chemical compounds.
The MDA-MB-468 cells were grown in serum-deprived DMEM overnight and then treated with
compounds VM23, VM25, VM26, and gefitinib for 6 h. The culture medium covering the cells attached
to the well surface was carefully transferred to tubes; the wells were gently washed with warm PBS,
and the wash solutions were collected in the same tubes. The collected samples were centrifuged, and
the pellets containing the putatively detached cells were treated with lysis buffer. Cells attached to the
surface of wells were separately collected and lysed. To increase the detection sensitivity of proteins in
putative detached cells, lysis was performed in smaller volumes compared with the attached cells.
The cytoskeleton proteins β-actin and α-tubulin, Hsp90α, and traces of EGFR were detected in the
culture medium collected from the attached cells, thereby proving the detachment of the cells treated
with compounds VM25 and VM26 or gefitinib for comparison (Figure 5a). As the loading control of
total proteins was not an appropriate means to assess the cell detachment, we used a ratio of each
protein in potentially detached cells to the attached cells treated with a given compound for evaluation.
Quantitative estimation of relative levels of individual proteins in the same cultures revealed higher
levels of the proteins in the detached cells after exposure to VM25, VM26 and gefitinib compared with
Cancers 2019, 11, 1094 8 of 23
VM23 or vehicle (Figure 5b). Curiously, the detachment of cancer cells promoted by the potent TKI
gefitinib (Figure 5a) was not described in a large number of studies when the amount of total protein
in cell extracts was adjusted to the same concentration to be loaded.
Figure 5. Small compounds promote detachment of cancer cells. MDA-MB-468 cells were treated with
25 µM of the compounds VM23, VM25, VM26 or gefitinib (Gef) in serum-deprived medium for 6 h (a),
with 25 µM of the compounds VM22-VM25 in serum-deprived medium for 48 h (c) or with 50 µM
of the compounds VM22-VM25 in FBS-supplemented medium for 48 h (e). The relative levels (%) of
proteins in detached cells were estimated as a ratio of the detached cells (Det) to the attached cells (Att)
(b) or β-actin (d,f). The detached cells were lysed in one-quarter (a,b) or one-tenth of the volume of the
attached cells (e). The differences in the volume of lysed buffer used were considered to normalize the
abundance of proteins.
To compare the ability of five compounds, VM22-VM26, to detach the cells, the treatment in
serum-deprived medium was prolonged for 48 h. The cells treated with VM22, VM23 or vehicle
displayed similar profiles of EGFR, Hsp90α, α-tubulin and β-actin in the attached cells, and except
EGFR, the three other proteins were detected in the detached cells (Figure 5c). In contrast, the cells
treated with VM25 or VM26 displayed almost no EGFR, Hsp90α, andα-tubulin and significant decrease
in β-actin levels in the attached cells. Moreover, none of the first three proteins was detected in the
detached cells as an indication of cancer cell death.
The ability of the compounds to promote the detachment of cells was also studied after 48 h
of growth in DMEM supplemented with FBS. Given that FBS contains a broad spectrum of growth
factors, including EGF [32], the cells were incubated with higher concentrations of the compounds
VM22-VM26. No significant differences were detected in the protein levels in the attached cells treated
with VM22, VM23 or vehicle (Figure 5e). In contrast, compounds VM25 and VM26 exhibited an
elevated capacity to decrease the expression levels of EGFR, Hsp90α, and α-tubulin in attached cells.
Cancers 2019, 11, 1094 9 of 23
In attempts to quantitatively assess the efficiency of cell detachment after longer exposure to
the compounds, we estimated the ratio of β-actin in the detached cells versus the attached cells, as
only this protein was detected in all 48-h treated cell samples. In the medium supplied with FBS,
cell detachment was clearly detected with VM24, VM25, and VM26 (Figure 5f), whereas the effect of
these compounds appeared to be less evident after growth in serum-deprived medium (Figure 5d).
Obviously, the abundance of only β-actin in the detached cells underestimates the efficiency of the
compounds, as higher stability of β-actin or re-adhesion of survived cells could misrepresent the
actual situation.
In fact, small compounds exhibited moderate to low toxicity in MDA-MB-468 cells (Supplementary
Table S2). The toxicity of the active compounds VM25 and VM26 was similar to that of gefitinib and
close to values determined previously for this potent TKI by other authors [33]. The kinetics of the
cell viability in complete media indicated a time-dependent killing effect of the compounds VM25
and especially VM26 on MDA-MB-468 and A549 cultures during a 72-h incubation (Supplementary
Figure S4).
Taken together, these results showed that endocytic degradation of EGFR leads to depletion of the
receptor, which drastically destabilizes the cytoskeleton, leading to the detachment of cancer cells from
the ECM and, ultimately, to death, resembling apoptotic anoikis.
2.5. Bim Expression is Temporarily Up-Regulated in Starved Cancer Cells upon Exposure to VM26
To determine whether the destabilization of cytoskeleton machinery by the compounds is related
to the status of the sensor protein Bim, protein expression was assessed first with immunofluorescence
imaging. The fluorescent signal emitted by Bim was significantly enhanced in the cells at exposure to
2.5 µM VM26 for one hour compared with the vehicle (Figure 6a).
This observation was verified by studying the kinetics of Bim expression and phosphorylation
in 12-h FBS-deprived cultures incubated further with 25 µM VM26 for 6 h in FBS-deprived and
nondeprived media. The MDA-MB-468 cells treated in FBS-deprived medium displayed essentially
increased BimEL expression after one-hour exposure to the compound, but the protein level decreased
after a longer, three-hour exposure (Figure 6b). Notably, high levels of BimEL were associated with an
essential decrease in the abundance of EGFR after one-hour exposure to VM26. The expression of the
lysosomal protease LAMP-2 and the cytoskeletal protein β-actin declined later compared with EGFR
in the starved culture. In parallel series of experiments with nonstarved MDA-MB-468 cultures, the
BimEL level was low and the decrease in the levels of other proteins could be observed after a longer,
six-hour incubation with VM26.
The efficacy of VM26 on the degradation of EGFR, LAMP-2, and β-actin was quantified by
comparing a ratio of corresponding proteins in starved cells versus nonstarved cells (Figure 6c).
The histograms clearly demonstrate that the reduction in the ratio of EGFR in the starved cells is faster
and substantially greater compared with β-actin. This two-speed decrease in the abundance of proteins
obviously reflected two processes, the early and rapid endocytic degradation of EGFR followed by a
slower disintegration of the cytoskeleton due to Bim sequestration.
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Figure 6. The compound VM26 promotes sequestration of Bim in MDA-MB-468 cells. (a) Bim response
to the compound VM26. Treatment conditions were similar to Figure 3c; the immunofluorescent
detection was carried out in permeabilized cells with anti-Bim mAb. (b) Kinetics of protein expression
in the cells treated with 25 µM VM26. (c) Relative levels of proteins were estimated as their ratio in
starved cells to nonstarved cells considering 100% of each protein in nonstarved cells. (d) Impact of
the addition of EGF (200 ng/mL) and glutamine (2.0 mM) on protein profiling in cells left untreated or
treated simultaneously with 25 µM VM26 for 6 h in FBS-deprived medium. Proteins were extracted in
moderate-strength lysis buffer. The EGFR monomer (M) and dimer (D) are shown.
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2.6. Glutamine Starvation Enhances Small Compound-Promoted Sequestration of Bim
To clarify the underlying factors involved in small compound-induced sequestration of Bim,
protein profiles were assessed with only compound VM26 and compared after the addition of its
mixture with EGF or glutamine or both into a 24-h the FBS-deprived medium containing overnight
starved cultures and cultivation continued for 6 h.
The analysis of the protein abundance in control assays with the vehicle showed that six-hour
cultures of MDA-MB-468 display slightly higher expression levels of β-actin after the addition of EGF,
glutamine or both, and the increase levels of EGFR monomer and dimer forms after the addition
of EGF (Figure 6d). Meanwhile, glutamine and the mixture of EGF with glutamine, and to a lesser
extent EGF, increased the expression of BimEL compared with the vehicle or EGF alone. Moreover,
a significant increase in the rate of phosphorylation was detected at Ser69 of BimEL, which is associated
with the enhanced expression of the sensor protein, and likely with the enhanced phosphorylation at
Tyr1068 of EGFR. Therefore, the completion of the medium with a fresh portion of glutamine improves
the functional state of BimEL.
The cells treated with VM26 in the presence of EGF, glutamine or both displayed an increase in the
expression levels of EGFR, LAMP-2, β-actin, and a cleaved caspase 3 compared with low expression
of the proteins in the presence of the compound (Figure 6d). The expression of BimEL essentially
increased after exposure of cells to VM26, and no reasonable modulation was detected after addition of
EGF, glutamine or the mixture EGF and glutamine to the medium. However, in contrast to the results
of control assays with vehicle, VM26 strongly suppressed Ser69 phosphorylation in BimEL, likely
associated with the decreased phosphorylation in EGFR, regardless of the addition of EGF, glutamine
or both to the growth medium.
We also assessed the effect of VM26 on the DU-145 prostate cancer cell line, characterized by an
unusual decrease in EGFR level in response to EGF action in the autocrine loop, presumably associated
with endocytosis [34]. Expression levels of EGFR decreased one hour after the addition of EGF or
VM26 in serum-deprived RPMI-1640 (Supplementary Figure S5a). In both cases, depletion of the
receptor did not affect LAMP-2 and β-actin levels, whereas it increased BimL and BimEL levels and
stimulated Ser69 phosphorylation. However, the depletion of EGFR under the action of VM26 for three
hours resulted in a decrease in BimEL expression and possibly Ser69 phosphorylation in the attached
cells. In the meantime, a greater number of cancer cells appear to detach from the ECM, compared to
the vehicle (Supplementary Figure S5a,b).
The VM26-promoted detachment of cancer cells, associated with depletion of EGFR, was
particularly apparent with prolonged treatment. After a 24-h incubation, VM26 resulted in the
disappearance of EGFR and β-actin, and only traces of LAMP-2 or Bim could be detected in the
attached cells, regardless of the addition of EGF or glutamine in the starvation medium (Supplementary
Figure S5c).
These results highlight the efficacy of VM26 in the dramatic degradation of EGFR in broad levels
of receptor gene expression in MDA-MB-468 and DU-145 cancer cells during EGF starvation. It can be
assumed that the medium devoid of FBS becomes also deprived of glutamine with longer growth of
cancer cells. The dual starvation for EGF and glutamine makes cells more vulnerable to VM26 invasion,
thereby accelerating compound-induced EGFR depletion and increasing cytoskeleton instability caused
by Bim sequestration.
2.7. Compound VM26 Weakly Inhibits EGFR Phosphorylation
We examined whether the suppression of EGFR phosphorylation resulted from only the protein
degradation or whether the small compound also inhibited the tyrosine kinase site. MDA-MB-468
cells grown in serum-deprived medium were incubated with the most active compound, VM26, for
short time periods, 10 and 20 min, and then, EGFR phosphorylation was stimulated by the incubation
of the cells with EGF for 5 min. The decrease in tyrosine phosphorylation at Tyr1068 was detected
only after 10-min exposure to VM26, whereas gefitinib, used as reference TKI, strongly inhibited EGFR
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phosphorylation at both 10-min and 20-min exposure times (Figure 7a). Therefore, the ability of VM26
to transiently prevent tyrosine phosphorylation of EGFR by the cognate ligand EGF characterizes
the compound as a reversible and weak ATP competitor that shows inhibitory potency only within a
short time.
Figure 7. Compound VM26 weakly suppresses EGFR phosphorylation. (a) EGFR expression and
tyrosine phosphorylation at Tyr1068 were evaluated in MDA-MB-468 cells after exposure to 25 µM
VM26 or gefitinib (Gef) for 10 min and 20 min. The cells were stimulated with EGF (200 ng/mL) for
5 min. Modeling of interactions between representative small compounds and the EGFR catalytic
domain. (b) A 3D view of the superposition of EGFR bound to VM23 (orange), VM25 (pink), and
VM26 (green) and gefitinib (yellow). Nitrogen, oxygen, and sulfur atoms are represented as blue,
red and yellow spheres, respectively. The αCβ4 loop containing Met766 corresponds to the region
between 761 and 781 amino acid positions. (c) Close-up view of the compound VM26 accommodation
in the hydrophobic cavity (green) in the tyrosine kinase domain. The amino acids Met766, Phe856,
Leu788 and Leu858 form the cavity, and Cys797, Arg803, and Arg841 are located in the catalytic pocket
(salmond) (see also Supplementary Figure S4).
2.8. Binding of Small Compounds Results in Dynamic Structural Rearrangements in EGFR
The compounds VM22-VM26 perfectly docked in the tyrosine kinase catalytic pocket of EGFR of
the highly resolved 3D structure 3W32 [35] by demonstrating negative free energy values comparable
to gefitinib (Supplementary Table S3). The analysis of the VM23, VM25, and VM26 interactions showed
a similar set of virtual contacts with amino acids in the best-docked conformations (Supplementary
Table S4).
To examine the binding process of similar molecules to EGFR, we employed molecular dynamics
(MD) simulations. The root mean square deviation (RMSD) of the molecular interactions was monitored
between EGFR and the compounds VM23, VM25, and VM26 and the well-characterized drug gefitinib
for comparison. The RMSD curves of the free molecules and the EGFR protein backbone were stable
throughout monitoring for 500 ns of simulation (Supplementary Figure S6). The virtual VM23/EGFR
complex was stable until the end of the simulation. Conversely, a remarkable shift was monitored in
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the dynamics of VM26 binding to the protein at 100,000 ps and VM25 binding at 300,000 ps, indicating
structural rearrangements in the compound-protein complexes. No shifts were detected with VM23
and gefitinib under the conditions used despite of rather similar distances between the molecules and
the selected amino acids in the bound structures (Supplementary Table S5).
At the beginning of the interactions, the carboxylate group in the furan moiety of VM23, VM25 and
VM26, which is exposed to solvent, establishes tight contacts with the guanidinium moiety of Arg803
located in the catalytic pocket (Figure 7b and Supplementary Figure S7). The furan moiety of VM23
also makes contacts with Cys797 and Arg841; this configuration of the bound protein is not subject to
structural changes, at least within 500 ns. In contrast, the carboxylate in the extremity of the furan
moiety in VM26 turns from Arg803 to Arg841, leading to the formation of a hydrogen bond. Moreover,
the furan and imidazole moieties in VM26 establish interactions with Cys797. Similarly, in compound
VM25, interactions between the imidazole moiety and Cys797 are associated with delayed dynamic
rearrangements, which shift the binding from Arg803 to Arg841. The alkyl chain at the extremity of
the three molecules is accommodated within a hydrophobic pocket terminated by Phe856 (Figure 7c,
Supplementary Figure S7 and Supplementary Video S1). The short CH3CH2 chain of VM23 is not
bulky enough to fill the hydrophobic pocket, whereas the longer CH3(CH2)4 chain of VM26 almost
completely occupies the pocket.
Crucially, the position of this hydrophobic pocket corresponds to the allosteric site discovered
recently in EGFR-bound complexes with two molecules, EAI001 and EAI045 [36]. Our docking analysis
revealed that the compound VM26 shares similar amino acid interactions with EAI045 bound to
the wild-type EGFR (PDB ID 2GS7) and the mutant T790M/V948R (PDB ID 2JIV), according to the
best-score generated conformations (Supplementary Figure S8, Supplementary Table S6). As far as
VM22–VM26 compounds are larger, they establish more amino acid contacts, which could increase the
binding affinity for EGFR (Supplementary Table S7).
3. Discussion
This work demonstrates an alternative strategy to interrupt the aberrant EGFR-mediated
phosphorylation cascade in cancer through authentic degradation of the receptor rather than strong
inhibition of the tyrosine kinase site. The furfuryl derivatives of 4-allyl-5-[2-(4-alkoxyphenyl)quinolin-
4-yl]-4H-1,2,4-triazole-3-thiol reversibly and weakly bind to the catalytic site of EGFR and induce
protein degradation, resulting in the detachment of cells from the ECM. Given that the binding
of our molecules to the catalytic pocket extends into the allosteric site, they can be categorized as
anti-EGFR molecules of the fourth generation, to which belong recently described TKIs, EAI001 and
EAI045 [37]. The druggable potency of compounds VM22-VM26 relies on two distinct routes, started
by EGFR endocytosis and continued by Bim sequestration-mediated disintegration of the cytoskeleton.
Obviously, the compound-induced endocytosis of EGFR is of particular importance, as the depletion
of significant amounts of the receptor has detrimental consequences for cell viability.
The cytoskeleton machinery is composed of polymers of actin and microtubules formed by tubulin,
which in concert with other proteins allow integrins to attach cells to the ECM [38]. Bim is a sensor protein
that initiates the intrinsic apoptotic pathway in healthy and diseased cells, and its phosphorylation
status, which is required for interactions with actin and microtubules to ensure the integrity of the
cytoskeleton machinery, depends on various factors operating at the transcriptional, translational, and
post-translational levels [21]. EGFR governs the stability of the cytoskeleton through the MAPK/ERK
pathway by phosphorylating Ser69 of the Bim isomers BimL and BimEL [39,40]. The phosphorylation of
Bim isomers at Ser69 leads to ubiquitin-dependent or ubiquitin-independent 26S proteasome-mediated
degradation of the protein in mice and rat apoptotic models [21]. The treatment of cancer cells with
potent EGFR TKIs has been shown to increase BimL and BimEL expression levels [40,41]. In any
case, the sequestration of Bim through a variety of signaling and metabolic pathways sensitizes the
cytoskeleton to autophagy [42].
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Our study suggests a plausible mechanism of action of polyfunctional heterocyclic compounds and
the course of events that cause BimEL sequestration-mediated degradation of the cytoskeleton, leading
to cancer cell detachment-promoted death (Figure 8). The action of new compounds is phenotypically
similar to the programmed apoptosis, anoikis, whereas the chemical invasion leads to the “forced
death” that is different from a natural process.
Figure 8. The proposed mechanism of the action of EGFR degraders on cancer cells. The binding
of EGF to the extracellular region of the receptor monomers results in rearrangements favorable to
the formation of functionally active homodimers that trigger downstream signaling pathways [1].
The compound VM26 binds to the tyrosine kinase catalytic pocket extended into the hydrophobic
allosteric site inducing EGFR trafficking and degradation in endosomes (microautophagy). The
depletion of EGFR results in Bim sequestration that leads to cytoskeleton disintegration, and ultimately
to cancer cell detachment from the extracellular matrix. Glutamine starvation causes the deficiency
of α-ketoglutarate and thereby, the inability of cells to replenish the tricarboxylic acid (TCA) cycle
and produce ATP. Dual starvation for EGF and glutamine accelerates and reinforces the cytoskeleton
disintegration leading ultimately to cancer cell detachment-promoted death.
Binding of the most active compound, VM26, to EGFR enhances endocytic degradation and
essential depletion of the receptor protein, leading to up-regulation but no phosphorylation of BimEL.
Therefore, the inactive sensor protein cannot provide the maintenance of functional relationships
and the integrity of cytoskeleton proteins in cancer cells. The withdrawal of serum from the growth
medium, which is the source of EGF [32] and competes with the active compound VM26 for binding to
EGFR, accelerates the cytoskeleton degradation and detachment of cells from the ECM.
However, glutamine starvation also plays a crucial role in strengthening protein degradation with
VM26. The addition of the cognate ligand EGF to continuously FBS-starved culture in the absence of the
compound weakly improved BimEL expression but not protein phosphorylation (Figure 6). Meanwhile,
when only glutamine was added to the starvation culture, it increased the phosphorylation rate of
BimEL in the absence of VM26 but not in the presence of the compound. Therefore, the expression and
phosphorylation rate of BimEL upon the treatment with the compound VM26 is dynamic process that
is modulated by the availability of both cognate ligand(s) and energy resources for EGFR activation.
We questioned how glutamine starvation affects signaling pathways initiated by EGFR and why
the deficiency in glutamine strengthens the potency of VM26 to kill cancer cells. First, cancer cells
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are fast-growing cells and require more energy in the form of ATP for protein synthesis than normal
cells [43]. Second, the addition of glutamine to the growth medium is necessary for many tumor cell
lines, not only because of the instability of this amino acid at 37 ◦C but also as a source of energy for
cellular metabolism [44]. Third, glutamine is enzymatically converted into α-keto-glutarate, which
merges with the TCA cycle to provide high levels of ATP production [45]. Fourth, EGFR requires ATP
not only to activate the catalytic ATP-binding site but also to phosphorylate many amino acids, including
seven tyrosine residues, even if the receptor undergoes endocytosis [46]. Fifth, the ATPase activity of
the chaperone Hsp90α provides energy-dependent correction of a large number of misfolded client
proteins to protect them against ubiquitination and 26S proteasome-promoted degradation [47]. As the
levels of Hsp90α decrease with the depletion of EGFR (Figures 3 and 5), misfolded glutamine-prone
proteins become accessible to protease degradation. Therefore, the dependence of EGFR activation
and related processes on glutamine can be formulated as “no glutamine, no EGFR signaling”.
Glutamine starvation has been applied for cancer therapy [48]. In this regard, recent data have
demonstrated that a potent TKI of EGFR, erlotinib, in combination with the glutaminase inhibitor
CB-839 severely affects metabolic and energetic balances, leading to apoptotic death of NSCLC cancer
cells [49]. The dual starvation for glutamine and EGF, resulting in the deficiency of ATP and the
weakness of EGFR functions, accelerates and reinforces the autophagic protein degradation in cancer
cells exposed to the compound VM26. Obviously, the rate of glutamine consumption primarily
determines the fate of cells, which can be nuanced by the influence of other factors on reprogramming
cellular processes, which may explain the variability in the time required for Bim sequestration
and cytoskeleton disintegration observed in our experiments. Therefore, further clarification of
small compound invasion in the modulation of EGFR signaling and glutamine metabolism axis is of
undeniable interest towards improving treatment strategies for tumors.
Another important issue in our study is the identification of a putative molecular switch for EGFR
endocytic degradation. The structure-activity relationship analysis strongly suggests that receptor
degradation is a feature determined by carboxylic acid extremity. Indeed, in contrast to the compounds
VM25 and VM26, two other compounds, VM20 and VM21—which have the same structure except for
the ester group instead of the carboxylic acid (Figure 1)—were not able to promote degradation of
EGFR under the conditions used (Figure 2a). In this regard, the presence of the carboxylate group
in the furan moiety of compounds determines the accommodation of the hydrophobic alkyl-ether
chain in the hydrophobic allosteric pocket located in the immediate vicinity of the ATP-binding site
(Figure 7b,c). Furthermore, the cytotoxicity of small compounds correlates with protein degradation
and cell-detachment abilities, showing the following order of efficacy: VM26 > VM25 > VM24 > VM23
> VM22. This order correlates with the length of the alkyl-ether chain in their structures, CH3(CH2)4,
CH3(CH2)3, CH3(CH2)2, CH3CH2, and CH3, respectively (Figure 1). Therefore, the more the alkyl
chain CH3(CH2)n occupies the hydrophobic allosteric pocket, the greater the EGFR degradation is,
which correlates with increased detachment of cancer cells from the ECM and toxicity of compounds
in breast cancer cells.
One can postulate that the local hydrophobicity of the allosteric pocket, enhanced by the
longer alkyl-ether chains in compounds, is used as a signal for proteases to attack the bound small
compound-EGFR complexes in lysosomes. According to MD analysis, the reorientation of the
compounds VM25 and VM26 from Arg803 to Arg841 is consistent with the participation of Arg841
in dynamic changes preceding the sulfenylation of Cys797 [9]. This structural rearrangement leads
to the positioning and likely direct interaction of longer alkyl-ether chains with Met766 in the αCβ4
loop, which is located in the proximity to the EGFR ATP-binding site (Figure 7b) and is likely to be
recognized by Hsp90α [50]. Structural changes caused by the compounds may also disrupt physical
interaction of EGFR with Beclin 1, which, when phosphorylated, suppresses autophagy by modulating
the Beclin 1 interactome [51]. In any case, the depletion of EGFR by small chemical degraders leads to
the exclusion of the receptor from a global control of the integrity of the cytoskeletal machinery.
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The apoptotic death of cancer cells caused by chemical agents that enhance protein degradation has
attracted increased attention in fighting cancer drug resistance [52]. The targeted degradation of proteins
was first demonstrated by the construction of a ubiquitin ligase fusion protein [53]. The approach,
known as PROTAC (Proteolysis Targeting Chimeric Molecule) [54], has been successfully used to
specifically degrade protein kinases, including resistance to chemotherapy EGFR mutants by tagging
potent inhibitors gefitinib, lapatinib or afatinib with a ubiquitination-sensitive module to sensitize
the receptor protein to proteases [55]. Our independently performed research highlights that EGFR
degradation can be alternatively and efficiently achieved with weak reversible EGFR inhibitors through
the allosteric site, without conjugation of ubiquitin degradation-sensitive tags to potent TKIs.
The chemotherapeutic interruption of MAPK/ERK phosphorylation flux has been considered a
promising means to reduce metastatic dissemination and attenuate cancer progression [56]. In this
regard, anti-EGFR inhibitors of the fourth generation demonstrate more selective binding to EGFR
compared with other tyrosine kinase proteins, and this highlights a considerable advantage of allosteric
inhibitors over catalytic site inhibitors in terms of therapeutic expectations [36,57]. According to our
data, allosteric binders enhance EGFR degradation, which can largely compensate for weak inhibition
of the catalytic site in breast cancer cells. The compound VM26 demonstrates high protein degradation
in EGFR-positive prostate cancer, which appears to be naturally tolerant to anti-EGFR therapy in clinical
studies [58]. In addition, the first in vivo assays showed promising results of our EGFR degraders in
inhibiting the tumor growth in mice [59].
Inspired by these results, we put forward the hypothesis that targeting the allosteric site with
weak reversible inhibitors, but potent degraders, can provide less brutal disruption of a variety of
interconnected signaling and metabolic pathways, governed by EGFR, and lead to more selective
killing cancer cells. This treatment may decrease secondary effects related to unpredicted aberrant
consequences caused by potent TKIs in cancer and healthy cells. Therefore, targeting EGFR degradation
through the drug-bound allosteric site in combination with glutamine starvation may be a rational and
patient-friendly means for the treatment of EGFR-driven tumors.
4. Materials and Methods
4.1. Chemicals and Reagents
Gefitinib (ZD1839) and canertinib (CI-1033) were purchased from Sigma-Aldrich and Santa Cruz
Biotechnology, respectively. Stock solutions of synthesized and commercial chemical compounds
were prepared in DMSO (99.9% purity, OriGen Biomedical, Austin, TX, USA), and aliquots were
stored at −80 ◦C. Tissue culture plastic wares (Nunc, Roskilde, Denmark) were used for growth of
adherent cancer cells. Protease and phosphatase inhibitor cocktail tablets and anti-human anti-ErbB2
antibody were purchased from Thermo Fisher. Anti-phospho-EGFR (Tyr1068), anti-Hsp90α, and
anti-HDAC2 antibodies were obtained from R and D Systems. Anti-EGFR (the epitope in the
cytoplasmic region), LC3α/β, anti-LAMP-2, anti-β-actin, anti-Bim mouse monoclonal antibodies,
fluorescent BP-CFL 595-labeled mIgGk, horseradish peroxidase-conjugated (HRP)-labeled mIgGk, and
protein G-agarose were purchased from Santa Cruz Biotechnology (Heidelberg, Germany). Anti-EGFR
mAb (the epitope in the extracellular region) was obtained from Millipore. Anti-phospho-Bim (Ser69)
rabit mAb, HRP-labeled rabit mAb, and anti-phospho-Tyr (pTyr-100) mouse mAb conjugated to
biotin were purchased from Cell Signaling Technology. HRP-labeled mouse mAb and WesternSure
chemiluminescent substrate were obtained from Li-Cor (Lincoln, NE, USA). Chemical synthesis of
compounds was described previously [29]. The chemistry of the compounds VM22-VM26 is described
in Supplementary Text S1.
4.2. Cell Culture
The triple-negative breast cancer MDA MB468 cells (obtained from Dr. Helene Hurst, Queen
Mary University of London, UK) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM)
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supplemented with 10% (v/v) foetal bovine serum (FBS), 2 mM L-glutamine, penicillin (100 units/mL),
and streptomycin (100 µg/mL) in a humidified atmosphere of 5% CO2 in air. The non-small-cell
lung-cancer A549 cells (obtained from the ATCC) and prostate cancer DU-145 cells (obtained from
Dr. Fabrice Fleury, University of Nantes, France) were grown in RPMI-1640 supplemented with 5%
FBS (for A549) or 10% FBS (for DU-145), 2 mM L-glutamine and corresponding antibiotics. To assess
the action of the compounds in starved cultures, the cells were incubated in FBS-deprived media for
12–24 h. For stimulation of EGFR phosphorylation, compound-treated or nontreated cells were washed
in PBS and incubated in FBS-deprived medium in the presence of EGF (200 ng/mL). The cells were
washed two times in cold PBS, subsequently lysed in RIPA or Pierce IP lysis buffer supplemented with a
cocktail of protease and phosphatase inhibitors, and centrifuged at 12,000 g for 10 min. The supernatant
fraction was used for protein analyses.
4.3. Cell Viability
Cell viability assays were performed with a colorimetric method [60] and IC50 values were
calculated as an average of triplicate assays.
4.4. Cell Detachment Assay
Cell growth plates that mimic the ECM (Nunc) were used for cultivation of cancer cells. Culture
medium and 1× PBS-wash-off suspensions were carefully collected in one tube as a pool of putative
detached cells. After centrifugation at 12,000 g for 5 min, the supernatant was discarded and the pellet
was treated with lysis buffer. The rest of the cells attached to the well surface were separately lysed and
collected by centrifugation in another tube. The ratio of lysis buffer used for the treatment of detached
cells to attached cells in cultures grown in serum-deprived DMEM was 1:4 and for the treatment of
detached cells to attached cells in cultures grown in serum-supplemented DMEM was 1:10. The relative
efficiency of cellular detachment (%) was estimated as the ratio of individual protein levels in the
detached cells to attached cells. Cell detachment was also visually controlled with optical microscopy.
4.5. Western Blotting
Equal amounts of proteins or equal amounts of cells extracts were loaded onto the TGX
gradient (4–18%) gels (Bio-Rad France, Marnes-La-Coquette, France), separated by sodium dodecyl
sulfate-polyacrylamide electrophoresis (SDS-PAGE) and transferred onto a nitrocellulose membrane
with a Trans-Blot Turbo system (Bio-Rad). The transferred proteins were probed with primary
antibodies and then immunoreactive proteins were detected with HRP-conjugated secondary antibodies.
Chemiluminescent detection of proteins and quantification of the intensity of protein bands was
performed with a C-Digit scanner (Li-COR, Lincoln, NE, USA). Cell lysates pre-cleared with protein
G-agarose were used to detect Bim and phosphorylated Bim in the gel. Other conditions were described
previously [13]. Original images of Western blots are shown in Supplementary Figure S9.
4.6. siRNA Interference Knockdown of EGFR
Transfection of MDA MB468 cells with siRNA was performed with 60 pmol of human EGFR-specific
duplex siRNA or scrambled siRNA (control) according to the manufacturer’s recommendations (Santa
Cruz Biotechnology, Heidelberg, Germany). Transfected cells were allowed to recover in complete
DMEM for 48 h and then starved in FBS-free DMEM for 18 h before exposure to compounds VM25 or
VM26 for 2 h. The receptor silencing was approximately 40% with the EGFR siRNA compared with
the cells transfected with a scrambled siRNA in two independent experiments.
4.7. Confocal Immunofluorescence Microscopy
MDA MBT68 cells (5 × 104 cells per well) were transferred into 8-well µ-Slides (Ibidi) and starved
in FBS-deprived DMEM for 18 h, and then incubated with 2.5 µM of compounds for one hour at
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37 ◦C in the same medium. The cells were washed twice with cold PBS, immediately fixed with 4%
paraformaldehyde at room temperature for 10 min, permeabilized with 0.25% Triton X-100, and then
incubated with relevant antibodies at 37 ◦C for 60 min. The plasma membrane was visualized in
non-permeabilized cells anti-EGFR mAb (the epitope in the extracellular region) conjugated to Cy5.5
and prepared as described previously [61]. The anti-EGFR mAb conjugated to Cy5.5 was also used to
detect the receptor protein in the permeabilized cells. Proteins LC3α/LC3β and Bim were visualized
with corresponding mAbs followed by incubation with mIgGk BP-CFL 595 (dilution 1:500) at 37 ◦C for
60 min. To visualize the nucleus, cells were stained with DAPI (dilution 1:1000) for 15 min at room
temperature. The cells were viewed with a laser-scanning confocal microscope (Nikon A1RSi) and a
wide-field microscope (Nikon Eclipse E800). The images were recorded with NIS Element software
(V4.40) and processed with ImageJ software (NIH v1.52).
4.8. Molecular Docking
The X-ray crystal structure of the EGFR kinase domain in complex with a non-covalent
derivative of pyrimido [4,5-b]azepine scaffold (PDB 3W32) [35], and with allosteric inhibitors
EAI001 and EAI045 (PDB ID 2GS7) and (PDB ID 2JIV) [36] were used for docking studies with
compounds VM22-VM26. Molecular models of EGFR and chemical compounds were created in PDB
format using the ChemBioDraw Ultra 12.0 software package (http://software.informer.com/getfree-
chembio3d-ultra-12.0/). Minimization of the free energy of the compounds was conducted with the
MM2 program in the ChemBioDraw Ultra 12.0 software package. The analysis of the compound
interactions with the EGFR catalytic domain was performed with the AutoDock Vina software package
(http://vina.scripps.edu/index.html) as described by Trott and Olson [62]. Putative binding of small
compounds to EGFR was generated with the program AutoDock Tools 1.5.6rc3. The highest scoring
values of the nine conformations were calculated for each coupled ligand-protein interaction using the
Vina scoring function.
4.9. Molecular Dynamics
To examine the dynamics and stability of the small molecules interactions with the EGFR kinase
domain [35] molecular dynamics simulations were employed using GROMACS 5.1 software [63].
Amber03 and GAFF force fields were applied for the proteins and small molecules, respectively [64].
Each EGFR complex with a small molecule was simulated for 500 ns in explicit water. Energy
minimization was performed with the steepest-descent method until the maximum force was less
than 1000.0 kJ/mol/nm. MD simulations were performed with 10-fs time steps, and electrostatics
values were treated with a Coulomb cutoff of 11 Å. The dynamic systems were temperature-coupled
using the Berendsen algorithm with a 1.0 ps time constant [65], and isotropic pressure coupling was
employed using the Berendsen algorithm with a time constant of 1.1 ps. The results from the MD
simulations were analyzed with Gromacs utilities using Visual Molecular Dynamics (VMD) software
version 1.9.2 [66]. Calculations were performed on a Graphics Processing Unit accelerated cluster
(Synsight, Evry, France).
4.10. Statistical Information
Statistical analysis was performed with GraphPad Prism V6 Software. For individual value plots,
data displayed as mean ± standard error of the mean. P values for statistical analyses were obtained
with Student’s t test.
5. Conclusions
This study points to an alternative possibility in the fight against aggressive cancer by targeting
EGFR with furfuryl derivatives of 4-allyl-5-[2-(4-alkoxyphenyl)quinolin-4-yl]-4H-1,2,4-triazole-3-thiol.
New compounds have a low ability to inhibit EGFR-mediated tyrosine kinase activity. However,
binding to catalytic and allosteric sites located in close proximity to each other in the tyrosine
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binding domain, determines their ability to trigger rapid and enhanced endocytic degradation of
the receptor protein, leading to disintegration of the cytoskeleton and, ultimately, to cancer cell
detachment-promoted death. The course of these distinct events, which are linked through the Bim
sequestration, depends on the growth conditions and functional interplay preceding the cell death.
The implication of autophagy as a cytoprotective response to chemical invasion apparently explains
the low toxicity of EGFR degraders.
Targeting EGFR degradation to kill cancer cells, with less destructive effects on normal cells, is an
attractive and promising rationale for further investigations aiming to stop metastatic progression and
to override the drug resistance in EGFR-driven tumours.
Supplementary Materials: The following materials are available online at http://www.mdpi.com/2072-6694/11/
8/1094/s1. Figure S1: Protein degradation in MDA-MB-468 and A549 cells after 18-h treatment with increasing
concentrations of VM26 in FBS-deprived media, Figure S2. The enlarged image of Figure 3c. Immunofluorescence
detection of LC3α/β in MDA-MB-468 cells exposed to 2.5 µM VM26 for 1 h, Figure S3. The enlarged image of
Figure 4a–d. EGFR rapidly responds to the chemical invasion of small compounds in cancer cells, Figure S4:
Kinetics of the viability of MDA-MB-468 and A549 cells in the FBS-supplemented media during incubation with
the compounds VM25 and VM26 for 72 h, Figure S5. Protein expression and phosphorylation in DU-145 cells
treated with compound VM26. (a) Western blot of proteins in attached and detached cells after exposure to
200 ng/ml EGF or 25 µM VM26 for one and three hours in serum-deprived RPMI-1640 medium. The detached
cells were lysed on one-tenth of the volume buffer used for attached cells. (b) Estimation of relative levels of
the detached cells to the attached cells was carried out with anti-LAMP-2 mAb. (c) Protein profiling in cells left
untreated or treated simultaneously with 25 µM VM26 and EGF (200 ng/ml) or glutamine (2.0 mM), Figure S6:
Time dependence of the RMSD monitored during the formation of the complexes between EGFR and compound
(A) VM23, (B) VM25, (C) VM26 or (D) gefitinib. The RMSD monitored for the protein backbone in the absence
of a small compound (E), Figure S7: 2D representation of different types of interactions between EGFR and
compound VM23 (A), VM25 (B), VM26 (C) or gefitinib (D). Images come from the average geometries of the
molecular dynamic simulations during the last 50 ns, Figure S8: Comparison EAI045 and VM26 docking in
3D-resolved EGFR structures 2GS7 and 2JIV. The hydrogen bond is shown in the form of green chain, Figure S9:
Western blot original images, Table S1: Two-dimensional size of nucleus in MDA-MB-468 cells treated with vehicle
(DMSO 0.1%) and compound VM26 were measured from images in Figure 4, Table S2: Toxicity of the compounds
(IC50) in MDA-MB-468 breast cancer cells were measured after the grown in FBS-supplemented media for 72 h,
Table S3: Binding parameters for compounds VM22-VM26 were estimated by docking with the EGFR kinase
domain, Table S4: Docking of compounds VM23, VM25, and VM26 and amino acids in the EGFR kinase domain.
The three best docked configurations (Conf) and corresponding ∆G values of the bound compound-protein are
shown, Table S5: Distances between the small molecules and selected amino acids in the EGFR catalytic pocket.
Distances between the sulfur atom in compounds VM23, VM25, VM26 and Cys797 (-SH) or Arg841 (-O) were
measured using the average geometry of the bound structures in the catalytic domain. The azote in Gefitinib
(no sulfur in its structure) was used for the estimation of the distance from Cys797, Table S6: The best-score
docking of the reference molecule EAI045 and the compound VM26 in EGFR using 2GS7 and 2JIV structures.
Amino acid interactions with the compounds through hydrogen bonds are shown in red, Table S7: Comparison of
compounds EAI001, EAI045, and VM22-VM26 binding to human EGFR. Binding parameters were estimated by
molecular docking in 3D- structures 2GS7 and 2JIV. EAI001 and EAI045 were used as reference molecules, Text S1:
Characterization of compounds VM17-VM26, Video S1: Dynamic view of the superposition of small compounds
bound to EGFR.
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